NCT04798326View on ClinicalTrials.gov

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 25, 2019

Primary Completion Date

January 10, 2020

Study Completion Date

February 26, 2020

Conditions
Bone Tumor
Interventions
DRUG

MW032

Subjects would receive a single 120mg (1.7 mL) of MW032 through subcutaneous injection, on the first day of treatment.

DRUG

Xgeva®

Subjects would receive a single 120mg (1.7 mL) of Xgeva® through subcutaneous injection, on the first day of treatment.

Trial Locations (1)

255400

PKUCare Luzhong Hospital, Zibo

All Listed Sponsors
lead

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY

NCT04798326 - Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults | Biotech Hunter | Biotech Hunter